PO.ET02.12 · 实验与分子治疗

优化药物载体上靶向分子的密度以改善细胞摄取

Optimizing targeting molecule density on drug carriers to improve cellular uptake

海报缩略图:优化药物载体上靶向分子的密度以改善细胞摄取
编号 3095 展板 23 时间 4/20 02:00–05:00 区域 Section 16 主讲 Maria Lambros, MS;PhD
分会场 Novel Therapeutics and Drug Targets 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Maria Lambros, Manjot Kaur

Biotechnology and Pharmaceutical Sciences, Western University of Health Sciences, Pomona, CA

摘要 Abstract

中文摘要
目的:本工作的目的是确定载体上靶向分子的数量是否与细胞摄取的改善相关。xCT 转运体是一种细胞表面易化转运体,可将胱氨酸转入细胞并将谷氨酸转出。以脂质体作为载体,我们将不同量的靶向剂胱氨酸偶联至其表面以利用 xCT 转运体。我们在多种细胞系中评估了脂质体表面偶联不同水平靶向分子的脂质体制剂(A:中等,B:低,C:高)的细胞摄取。 方法:配制了偶联不同水平靶向分子的脂质体,并将荧光染料磺酰罗丹明 B(SRB)包封于脂质体中。所测试的制剂为:三种偶联不同水平靶向分子的靶向制剂(A:中等,B:低,C:高)、一种非靶向制剂(NT)以及一个未处理对照。这些制剂与五种人癌细胞系(BxPC-3、MIA PaCa-2、A549、OVCAR-8 和 PANC-1)孵育 6 小时。孵育后,将细胞系洗涤三次,并使用流式细胞术(Attune NxT 声聚焦细胞仪,Thermo Fisher Scientific,MA)通过测量 SRB 的平均荧光强度来定量脂质体摄取。 结果:在所测试的全部五种细胞系中,靶向脂质体始终表现出显著高于非靶向制剂的摄取。然而,靶向分子密度与摄取之间的相关性依赖于细胞系。靶向分子密度最高的制剂(制剂 C)在五种细胞系中的三种(BxPC-3、MIA PaCa-2 和 A549)中显示出最高摄取。相比之下,在 OVCAR-8 和 PANC-1 细胞系中,改变靶向分子密度并未导致靶向制剂间摄取的统计学显著差异。 结论:数据表明,细胞内化脂质体的能力取决于脂质体是否携带靶向分子。然而,内化的程度依赖于细胞系。
查看英文原文 English abstract
Purpose: The purpose of this work is to determine whether the number of targeting molecules on a carrier correlates with improved cell uptake. The xCT transporter is a cell-surface facilitative transporter that imports cystine into the cell and exports glutamate. Using liposomes as the carrier, we conjugated varying amounts of cystine, the targeting agent, to their surfaces to harness the xCT transporter. We evaluated the cellular uptake of liposomal formulations with different levels of the targeting molecule conjugated to the liposomal surface (A: medium, B: low, C: high) in several cell lines. Methods: Liposomes with different levels of the targeting molecule were formulated, and sulforhodamine B (SRB), a fluorescent dye, was encapsulated in the liposomes. The formulations tested were: three targeted formulations with varying levels of the targeting molecule (A: medium, B: low, C: high), one non-targeted formulation (NT), and an untreated control. These formulations were incubated for 6 hours with five human cancer cell lines (BxPC-3, MIA PaCa-2, A549, OVCAR-8, and PANC-1). After incubation, the cell lines were washed three times, and liposome uptake was quantified by measuring the mean fluorescence intensity of SRB using flow cytometry (Attune NxT, Acoustic Focusing Cytometer, Thermo Fisher Scientific, MA). Results: Targeted liposomes consistently demonstrated significantly higher uptake than the non-targeted formulation across all five cell lines tested. However, the correlation between targeting-molecule density and uptake was cell-line-dependent. The formulation with the highest targeting molecule density (Formulation C) showed the highest uptake in three of the five cell lines (BxPC-3, MIA PaCa-2, and A549). In contrast, varying the targeting molecule density did not result in a statistically significant difference in uptake among the targeted formulations in the OVCAR-8 and PANC-1 cell lines. Conclusion: The data suggest that cells' ability to internalize liposomes depends on whether the liposomes carry a targeting molecule. However, the extent of internalization is cell line dependent.
利益披露 Disclosure
M. Lambros, DoricPharma LLC ), Patent, Other, Founder of DoricPharma LLC. M. Kaur, None.

← 返回 AACR 2026 检索